HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: A clinico-pathologic study

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3826-3833

  Rossi, Elisa ^a   Grisanti, Salvatore ^b   Villanacci, Vincenzo ^a   Casa, Domenico Della ^b   Cengia, Paolo ^b   Missale, Guido ^b   Minelli, Luigi ^b   Buglione, Michela ^b   Cestari, Renzo ^b   Bassotti, Gabrio ^c  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adenocarcinoma; Barrett's oesophagus; Dysplasia; FISH; HER 2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROTO ONCOGENE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77449092867     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00517.x     Document Type: Article

References (45)

1. Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell. 2004, 6:11-6.
2. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol. 2006, 13:12-30.
3. Parkin DM, Bray F, Ferlay Y. Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55:74-108.
4. Kelloff GJ, Lippman SM, Dannenberg AJ. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer. A plan to move forward. Clin Cancer Res. 2006, 12:3661-97.
5. Reid BJ, Levine DS, Longton G. Predictors of progression to cancer in barrett's esophagus: baseline histology and flow cytometry to identify low- and high-risk patient subsets. Am J Gastroenterol. 2000, 95:1669-76.
6. Buttar NS, Wang KK, Sebo TJ. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001, 120:1630-9.
7. Conio M, Blanchi S, Lapertosa G. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol. 2003, 98:1931-9.
8. Oberg S, Wenner J, Johansson J. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg. 2005, 242:49-54.
9. Chang EY, Morris CD, Seltman AK. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg. 2007, 246:11-21.
10. Pepe MS, Etzioni R, Feng Z. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-61.
11. Reid BJ, Prevo LJ, Galipeau PC. Predictors of progression in Barrett's esophagus. II: baseline 17p (p53) loss of heterozigosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001, 96:2839-48.
12. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am. 2003, 13:369-97.
13. Schulmann K, Sterian A, Berki A. Inactivation of p16, RUNX3 and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene. 2005, 24:4138-48.
14. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999, 9:125-38.
15. Merrick DT, Kittelson J, Winterhalder R. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res. 2006, 12:2281-8.
16. Rossi E, Villanacci V, Bassotti G. HER-2/neu in Barrett esophagus. A comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol. 2006, 15:125-30.
17. Sampliner RE. Practice parameters Committee ACG: update guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2002, 97:1888-95.
18. Cengia G, Missale G, Minelli L. Screening for and surveillance of Barrett's esophagus is clinically indicated. Dig Dis. 2007, 25:197-202.
19. Conio M, Repici A, Cestari R. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol. 2005, 11:6650-5.
20. Cestari R, Villanacci V, Rossi E. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study. Cancer Lett. 2007, 251:278-87.
21. Lopes CV, Hela M, Pesenti C. Circumferential endoscopic resection of Barrett's esophagus with high-gradedysplasia or early adenocarcinoma. Surg Endosc. 2007, 21:820-4.
22. Hamilton SR, Aaltonen LA. WHO pathology and genetics: tumors of digestive system 2000, Lyon, IARC Press
23. Villanacci V, Rossi E, Zambelli C. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Dig Liver Dis. 2007, 39:305-11.
24. Villanacci V, Bellone G, Battaglia E. Ski/SnoN expression in the sequence metaplasma-dysplasia-adenocarcinoma of Barrett's esophagus. Hum Pathol. 2008, 39:403-9.
25. Dako Hercep Test: Anti-Her2 IHC System for Immunoenzymatic Staining. 2000, package insert, Carpinteria, CA, USA, Dako Corp
26. Ishikawa T, Kobayashi M, Mai M. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol. 1997, 151:761-8.
27. Walch A, Bink K, Gais P. Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal Cell Pathol. 2000, 20:25-32.
28. Ellis IO, Dowsett M, Bartlett J. Recommendations for HER2 testing in the UK. J Clin Pathol. 2000, 53:890-2.
29. Ellis IO, Bartlett J, Dowsett M. Best Practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004, 57:233-7.
30. Sharma P, Falk GW, Weston AP. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2006, 4:566-72.
31. Lim CH, Treanor D, Dixon MF. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy. 2007, 39:581-7.
32. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998, 3:237-52.
33. Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999, 26:108-16.
34. Pauletti G, Dandekar S, Rong H. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000, 18:3651-64.
35. Ross JS, Fletcher JA, Bloom KJ. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004, 3:379-98.
36. Rabinovitch PS, Longton G, Blount PL. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001, 96:3071-83.
37. Downs-Kelly E, Yoder BJ, Stoler M. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005, 29:1221-7.
38. Weston AP, Sharma P, Mathur S. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004, 99:1657-66.
39. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998, 16:413-28.
40. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344:783-92.
41. Berchuck A, Rodriguez G, Kamel A. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 1990, 76:381-7.
42. Chang JL, Tsao YP, Liu DW. The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix. Gynecol Oncol. 1999, 73:62-71.
43. Rygiel AM, van Baal JW, Milano F. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer. 2007, 109:1980-8.
44. Rygiel AM, Milano F, Ten Kate FJ. Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. Genes Chromosomes Cancer. 2008, 47:396-404.
45. Villanacci V, Rossi E, Grisanti S. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol Dietol. 2008, 54:347-53.